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Abstract 
Background: Omega-3 (ω-3) fatty acid (FA)-containing parenteral nutrition (PN) is associated with significant 
improvements in patient outcomes compared with standard PN regimens without ω-3 FA lipid emulsions. Here, we 
evaluate the impact of ω-3 FA-containing PN versus standard PN on clinical outcomes and costs in adult intensive 
care unit (ICU) patients using a meta-analysis and subsequent cost-effectiveness analysis from the perspective of a 
hospital operating in five European countries (France, Germany, Italy, Spain, UK) and the US.
Methods: We present a pharmacoeconomic simulation based on a systematic literature review with meta-analysis. 
Clinical outcomes and costs comparing ω-3 FA-containing PN with standard PN were evaluated in adult ICU patients 
eligible to receive PN covering at least 70% of their total energy requirements and in the subgroup of critically ill ICU 
patients (mean ICU stay > 48 h). The meta-analysis with the co-primary outcomes of infection rate and mortality rate 
was based on randomized controlled trial data retrieved via a systematic literature review; resulting efficacy data were 
subsequently employed in country-specific cost-effectiveness analyses.
Results: In adult ICU patients, ω-3 FA-containing PN versus standard PN was associated with significant reductions 
in the relative risk (RR) of infection (RR 0.62; 95% CI 0.45, 0.86; p = 0.004), hospital length of stay (HLOS) (− 3.05 days; 
95% CI − 5.03, − 1.07; p = 0.003) and ICU length of stay (LOS) (− 1.89 days; 95% CI − 3.33, − 0.45; p = 0.01). In 
critically ill ICU patients, ω-3 FA-containing PN was associated with similar reductions in infection rates (RR 0.65; 
95% CI 0.46, 0.94; p = 0.02), HLOS (− 3.98 days; 95% CI − 6.90, − 1.06; p = 0.008) and ICU LOS (− 2.14 days; 95% CI 
− 3.89, − 0.40; p = 0.02). Overall hospital episode costs were reduced in all six countries using ω-3 FA-containing PN 
compared to standard PN, ranging from €-3156 ± 1404 in Spain to €-9586 ± 4157 in the US.
Conclusion: These analyses demonstrate that ω-3 FA-containing PN is associated with statistically and clinically 
significant improvement in patient outcomes. Its use is also predicted to yield cost savings compared to standard PN, 
rendering ω-3 FA-containing PN an attractive cost-saving alternative across different health care systems.
Study registration: PROSPERO CRD42019129311.
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Background
Parenteral nutrition (PN) is offered to patients if oral or 
enteral nutrition is impossible, insufficient, or contrain-
dicated. One integral component of PN is lipids, as they 
provide an energy-dense source of calories, essential fatty 
acids (FA) and the building blocks for cell membranes [1, 
2]. A number of different sources for the lipid emulsions 
used in PN have been developed over time, the first of 
which was soybean oil [1]. One potential disadvantage of 
using emulsions containing soybean oil as the sole lipid 
source is the relatively high omega-6 (ω-6) polyunsatu-
rated fatty acid (PUFA) content: Over 50% of the FAs in 
soybean oil are comprised of linoleic acids [1, 3]. Follow-
ing concerns that ω-6 PUFAs might have pro-inflam-
matory and immunosuppressive properties, mixtures of 
different lipid sources were developed to partially replace 
linoleic acid and α-linolenic acid in PN with medium-
chain triglycerides, monounsaturated fatty acids from 
olive oil and/or eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA) from fish oil [1, 4]. Omega-3 
(ω-3) FAs derived from fish oil may offer clinical benefits 
across a wide spectrum of patients, including patients in 
an intensive care unit (ICU), due to their effects on anti-
inflammatory, immunomodulatory, and pro-resolution 
pathways [1, 3, 4].
Meta-analyses have demonstrated the positive impact 
of ω-3 FA-containing PN in comparison with standard 
PN (without ω-3 FA supplementation) on critically ill 
adults, with statistically significant reductions in hos-
pital length of stay (HLOS) [5–14], ICU length of stay 
(LOS) [8, 15], duration of mechanical ventilation [15, 
16] and decreased infection rates [7–9, 11–13, 17]. The 
risk of infection increases with longer HLOS [18] and a 
shorter ICU LOS reduces general deconditioning due to 
prolonged bed rest, sedation and immobilization, which 
negatively impact patient quality of life [19].
Patients treated in an ICU setting are a specific group 
within the overall population of hospitalized patients. 
ICU patients tend to have more severe medical condi-
tions and the treatment costs for ICU patients are gen-
erally higher than those for other patients in a routine 
hospital setting [20]. Critical illnesses can trigger acute 
metabolic changes leading to hypercatabolism [21]. Con-
sequently, patients are at high risk of developing energy 
and protein deficits during an ICU stay, resulting in loss 
of lean body mass and ICU-acquired weakness [22–30]. 
In critically ill patients, hypercatabolism is associated 
with poor clinical outcomes, which can be counteracted 
by appropriate feeding [22, 23]. Adequate protein and 
calorie delivery are key for the maintenance and genera-
tion of muscle mass, strength and function [28, 31]. In 
ICU patients, hypocaloric or hypercaloric energy intake 
over a prolonged period increases the risk of negative 
clinical outcomes and results in higher infection and 
mortality rates as well as a longer duration of mechanical 
ventilation [22, 23, 32–36].
Meta-analyses and systematic reviews are important 
tools for clinicians and patients to inform treatment deci-
sions via the evaluation of health care intervention risks/
benefits and can provide a starting point for the develop-
ment of clinical practice guidelines [37]. Cost-effective-
ness analyses compare new interventions with current 
clinical practice in terms of costs and benefits; both of 
these outcomes may influence treatment decisions as 
well as guideline development [38]. A recent meta-anal-
ysis and the corresponding cost-effectiveness analysis in 
hospitalized patients treated with PN (i.e., patients in a 
general ward and/or in an ICU) confirmed that ω-3 FA-
containing PN is not only associated with clinical benefits 
compared to standard PN without ω-3 fatty acids but also 
with concurrent cost savings [8, 39].
While these results suggest clinical and economic ben-
efits in the hospitalized patient population as a whole, it 
was not designed to specifically inform the effects on the 
ICU population, which was a prespecified subgroup ana-
lyzed only, as appropriate, to investigate sources of heter-
ogeneity in the overall estimates. We could therefore not 
evaluate if the overall results would also apply to the ICU 
population, and even less in the subgroup of critically ill 
(as opposed to patients transiting in the ICU for post-
surgical weaning and monitoring). In this analysis on the 
population of ICU patients, we determine the influence 
of ω-3 FA-containing PN versus standard PN on clinical 
outcomes and simulate associated treatment costs across 
five European countries (France, Germany, Italy, Spain 
and the UK) and the US.
Methods
The present study is comprised of a meta-analysis and a 
cost-effectiveness analysis in order to evaluate the impact 
of omega-3 fatty acid-containing PN versus standard PN 
(not supplemented with ω-3 FA) on clinical outcomes 
and costs in adult ICU patients.
Meta‑analysis
Overview
The protocol for this study was published prospectively 
(PROSPERO CRD42019129311). In summary, the meta-
analysis included the following steps: (1) definition of eli-
gibility criteria, (2) identification of databases and search 
strategy, (3) structured literature search to identify pub-
lications, followed progressively by study selection based 
on title, abstract, and full text, and (4) data extraction and 
synthesis of the results.
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Patient population
This analysis included data from hospitalized adult ICU 
patients (as defined by the authors of each study) who 
were eligible to receive PN to cover at least 70% of their 
total energy requirements. Two groups of ICU-patients 
were investigated: (1) all patients treated in an ICU set-
ting (as defined by the authors of each study), and (2) 
a subgroup of ICU patients comprising “critically ill” 
patients (as defined by the authors of each study or with a 
mean ICU stay > 48 h). Non-target populations (i.e., pedi-
atric or neonatal patients, general ward) or enteral nutri-
tion studies were excluded.
Outcomes
The primary and co-primary outcomes were infection 
rate (any nosocomial infection) and mortality rate (30-
day mortality: any death occurring up to 30  days after 
receiving at least one dose of study treatment), respec-
tively. Secondary outcomes included HLOS, ICU LOS, 
sepsis rate and length of mechanical ventilation. Other 
outcomes included transfused blood units and oxy-
genation index, the fatty-acid composition of plasma 
phospholipids and the lipid profile (α-tocopherol, EPA, 
DHA, arachidonic acid, plasma triglycerides), markers 
of inflammation and antioxidant status (interleukin-6, 
leukotriene  [LT]  B5, LTB4, LTB5:LTB4 ratio, C-reactive 
protein, tumor necrosis factor [TNF]-α), and routine 
laboratory parameters (lactate; urea; serum creatinine; 
creatinine clearance; platelets; prothrombin time; partial 
thromboplastin time [PTT]; international normalized 
ratio; bleeding time; liver enzymes aspartate [AST] and 
alanine aminotransferase [ALT], and γ–glutamyl trans-
ferase [GGT]; and total bilirubin).
Statistical verification
Trial sequential analysis (TSA) was used to explore 
whether the cumulative evidence was sufficiently robust 
to reach conclusive results; i.e., whether the pooled anal-
yses were adequately powered to reliably evaluate the 
treatment effect on outcomes. A TSA was performed for 
all primary and secondary outcomes with a statistically 
significant pooled effect.
Meta‑bias
To determine the presence of reporting biases, we deter-
mined whether a protocol for the respective randomized 
clinical trial was published before its conduct. Studies 
with a published protocol were evaluated for selective 
reporting of outcomes (outcome reporting bias). Report-
ing biases were further explored via funnel plots if ≥ 10 
studies were available. To evaluate the confidence in 
the cumulative estimates for all statistically significant 
outcomes, the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) working group 
methodology was applied using GRADEpro v.3.6.1 [40].
Pharmacoeconomic analysis
Overview
Six separate cost-effectiveness models comparing ω-3 
FA-containing PN with standard PN (without ω-3 FA 
supplementation) in ICU patients were developed and 
simulated for hospitals in France, Germany, Italy, Spain, 
the UK and the US. The model generation included 
the following steps: (1) conceptualization of a logical 
structure for both patient cohorts [all ICU patients and 
critically ill ICU patients]; (2) identification of country-
specific outcomes for patients receiving standard PN 
in both cohorts; (3) identification of country-specific 
sources for drug acquisition and hospital service costs; 
(4) simulation of country-specific outcomes for patients 
receiving ω-3 FA-containing PN by applying the results 
of the meta-analysis; (5) calculation of the country-spe-
cific total cost per simulated patient; (6) analysis of the 
result’s sensitivity to input parameter uncertainty via 
deterministic and probabilistic sensitivity analyses (PSA). 
The models were based on a probabilistic discrete event 
simulation technique and developed in Excel (Microsoft 
Corporation, Redmond, WA, USA). Simulations were 
run over 10,000 iterations, with each iteration represent-
ing one patient. Costs were modeled in the currencies of 
each country (pound sterling [GBP] in the UK and US 
dollars [USD] in the US), but converted to euros (EUR) 
using the average exchange rate of January 2020 to facili-
tate comparability. The conversion rates were as follows: 
GBP-EUR 1.1759 and USD-EUR 0.9005.
Patient population
All models included two treatment arms (ω-3 FA-con-
taining PN and standard PN), with each patient pass-
ing simultaneously through both; i.e., both simulated 
alternatives run on the same cohort. Infection episodes, 
discharge from hospital, and death were evaluated. The 
latter two parameters defined the end of the patient path-
way, whereas the former only affected treatment costs.
Outcomes of the patient cohort were simulated accord-
ing to the PN treatment regimen they received and 
compared: ω-3 FA-containing PN versus standard PN 
(Additional file 1: Figure S1).
Country-specific patient outcomes for the standard 
PN receiving group relevant for the simulation (lengths 
of stay, death and infection rates) were retrieved in pub-
lished sources (Additional file 1: Table S1) and an appro-
priate distribution fitted to represent them in the model 
using the method of moments. Outcomes for the ω-3 
FA-containing PN group are simulated after applying the 
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relative efficacy estimates from the meta-analyses to the 
outcomes of the standard PN group.
Model cost inputs
The input parameters for ICU-patients in six countries 
(France, Germany, Italy, Spain, UK and US), such as daily 
costs, costs per infection, and costs for PN treatment, 
were extracted from published sources and are displayed 
in Additional file 1: Table S1.
For the European countries, the daily PN costs were 
based on current market shares and prices as well as 
the daily number of PN bags required per patient. For 
US daily cost estimations, daily lipid requirements were 
modeled based on patient age distribution [41] and 
patient weight in gender- and age-specific groups [42]. 
Costs of lipid emulsions were based on the lowest price 
for standard PN while using manufacturer prices for ω-3 
FA-containing PN.
Sensitivity analyses
Probabilistic and deterministic sensitivity testing 
approaches were used to determine the influence of 
model parameters on calculated estimates. A probabil-
istic sensitivity analysis (PSA) determines the effect of 
global parameter uncertainty on estimated costs. PSAs 
were performed by drawing parameter values from their 
respective probability distributions, thus creating 1000 
unique sets of parameter combinations. If data on uncer-
tainty were missing, a 20% standard deviation of the 
mean value with an appropriate probability distribution 
was used.
In deterministic sensitivity analyses, simulations were 
repeated while varying parameter values to their lower 
and upper confidence interval limits and keeping the 
remaining parameter values constant. In cases of unavail-
able confidence intervals, the lower and upper 95% confi-
dence interval limits of the distribution used in the PSA 
were assumed as parameter values.
Results
Systematic literature review and meta‑analysis
Study selection and characteristics
Four thousand and three publications were initially iden-
tified via database searches. Of these, 69  publications 
remained relevant after the titles and abstracts were 
screened by three independent reviewers. Following 
the evaluation of the full-text articles and the exclusion 
of publications that did not meet eligibility criteria, this 
number was further reduced to 24  studies (Additional 
file  1: Figure S2). Therefore, our meta-analysis of ω-3 
FA-containing PN versus standard PN includes 24  ran-
domized controlled trials with a total of 1421  patients 
receiving PN in an ICU setting (Additional file  1: 
Table S2).
Clinical outcomes
Overall, this meta-analysis showed a positive impact of 
omega-3 FA-containing PN on clinical outcomes for ICU 
patients. The relative risk for infection was reduced signif-
icantly by 38% with ω-3 FA-containing PN versus stand-
ard PN in ICU patients across 8 studies with 795 patients 
(relative risk [RR]  0.62; 95%  confidence interval [CI] 
0.45, 0.86; p = 0.004) (Fig. 1a). Similarly, critically ill ICU 
patients had a 35% RR reduction for infection with ω-3 
FA-containing PN (5 studies with 659 patients; RR 0.65; 
95% CI 0.46, 0.94; p = 0.02) (Fig. 1b). There was a not sig-
nificant trend towards a decreasing incidence of sepsis 
with ω-3 FA-containing PN (RR 0.56; 95% CI 0.26, 1.19; 
p = 0.13) in 3 studies with 336 ICU patients (Fig. 2). Sep-
sis was not evaluated for the subgroup of critically ill 
patients, as the minimum observation requirement was 
not met. ω-3 FA-containing PN was associated with a 
non-significant 10% relative risk reduction in 30-day 
mortality in all ICU patients and the subgroup of criti-
cally ill ICU patients across 12 studies with 925 patients 
(RR  0.90; 95%  CI 0.69,  1.16; p = 0.41) and 10  studies 
with 835 patients (RR 0.90; 95% CI 0.69, 1.16; p = 0.41), 
respectively (Fig. 3a, b). HLOS was reported in 11 stud-
ies with 872 ICU patients and 8 studies with 742 critically 
ill ICU patients: both patient groups exhibited signifi-
cant reductions in mean HLOS with ω-3 FA-containing 
PN of − 3.05 days (95% CI − 5.03, − 1.07; p = 0.003) and 
− 3.98  days (95%  CI − 6.90,  − 1.06; p = 0.008), respec-
tively (Fig. 4a, b). ICU LOS was also significantly reduced 
with ω-3 FA-containing PN versus standard PN in all 
ICU patients and critically ill ICU patients: 11  stud-
ies (890 patients) reported ICU LOS in the general ICU 
patient population, with a mean reduction of − 1.89 days 
(95%  CI − 3.33, − 0.45; p = 0.01) (Fig.  5a) and 9  studies 
with 826 patients reported a mean ICU LOS reduction of 
− 2.14 days (95% CI − 3.89, − 0.40; p = 0.02) in critically 
ill ICU patients (Fig.  5b). Length of mechanical ventila-
tion was reported in 6 studies (528 patients): Compared 
with standard PN, ω-3 FA-containing PN was associated 
with a non-significant reduction of − 0.02 days in length 
of mechanical ventilation (95% CI − 0.10, 0.05; p = 0.60) 
(Fig. 6). The relevance of statistically significant outcomes 
was verified with TSAs: all significant clinical outcomes 
showed adequate statistical power, meaning the results 
can be considered conclusive (Additional file  1: Figure 
S3). Hence, the beneficial effects of a lower infection rate, 
shorter HLOS as well as ICU LOS are indeed a conse-
quence of the application of an ω-3 FA-containing PN 
solution.
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Laboratory outcomes
Patients receiving ω-3 FA-containing PN also experi-
enced a significant benefit regarding several laboratory 
parameters compared with patients receiving standard 
PN: A liver parameter (ALT), inflammatory markers 
(interleukin [IL]-6, TNF- α, LTB4:LTB5 ratio), the lipid 
profile and composition (EPA and DHA) as well as the 
concentration of liposoluble vitamins (α-tocopherol) all 
significantly improved with the administration of ω-3 
FA-containing PN (Additional file 1: Table S3).
Confidence in cumulative estimates and meta‑bias
Confidence in the cumulative estimates of analyzed clini-
cal outcomes, according to the GRADE evaluation, was 
high for the clinical outcome infection rate and moder-
ate for HLOS and ICU LOS (Additional file 1: Table S4). 
Regarding laboratory parameters, confidence was either 
high or moderate. Funnel plots were used to evaluate 
potential meta-biases (reporting bias) in clinical out-
come analyses. The Funnel plots appeared symmetrical 
for 30-day mortality and HLOS and slightly asymmetrical 
Fig. 1 Infection rates in a all ICU patients and b critically ill ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: random 
sequence generation (selection bias); B: allocation concealment (selection bias); C: blinding of participants and personnel (performance bias); D: 
blinding outcome data (attrition bias); E: incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, confidence 
interval; FA, fatty acid; ICU, intensive care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
Fig. 2 Sepsis in ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: random sequence generation (selection bias); B: 
allocation concealment (selection bias); C: blinding of participants and personnel (performance bias); D: blinding outcome data (attrition bias); E: 
incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, confidence interval; FA, fatty acid; ICU, intensive 
care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
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for infection rate, ICU LOS and mechanical ventilation; 
however, no evidence for significant bias on the weighted 
regression was found using both Begg’s and Egger’s tests 
(Additional file 1: Figure S4).
Simulation and cost‑effectiveness
Pharmacoeconomic analysis
Additional file  1: Table  S1 summarizes all input param-
eters for ω-3 FA-containing PN and standard PN. The 
simulation results revealed that mean HLOS and mean 
incidence of infection with ω-3 FA-containing PN and 
standard PN varied widely between countries and treat-
ment groups (Table  1). The cost of PN acquisition was 
higher with ω-3 FA-containing PN in all countries ana-
lyzed except France (Table 2). Nevertheless, all five Euro-
pean and the US ICU settings investigated, the increased 
effectiveness of ω-3 FA-containing PN correlated with a 
decrease in mean cost per adult patient. Total cost reduc-
tions amounted to €-3652 ± 783 in France, €-4813 ± 1011 
in Germany, €-3342 ± 1254 in Italy, €-3156 ± 1404 
in Spain, €-5546 ± 436 (£-4986 ± 392) in the UK and 
€-9586 ± 4157 ($-10,672 ± 4628) in the US. In all six 
countries, expenses for infections and HLOS were lower 
with ω-3 FA-containing PN versus standard PN, with 
the US exhibiting the largest savings for both (infec-
tion: €-850 ± 5055/$-947 ± 4628; HLOS: €-8856 ± 0/$-
9869 ± 0). Spain and the UK had lowest cost savings 
with ω-3 FA-containing PN versus standard PN regard-
ing HLOS (€-2928 ± 0) and infections (€-65 ± 428/£-
58 ± 385), respectively.
Sensitivity analysis
The stability and robustness of the cost-effectiveness 
analyses were confirmed with sensitivity analyses. Results 
for the PSAs are depicted in Fig. 7: For all six countries 
analyzed, 99.7–99.9% of the 1000  incremental cost-
effectiveness ratio estimates, each using a different set 
Fig. 3 Thirty-day mortality in a all ICU patients and b critically ill ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: 
random sequence generation (selection bias); B: allocation concealment (selection bias); C: blinding of participants and personnel (performance 
bias); D: blinding outcome data (attrition bias); E: incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, 
confidence interval; FA, fatty acid; ICU, intensive care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
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of randomly drawn parameter values, verified that ω-3 
FA-containing PN was cost-saving when compared with 
standard PN. According to our analysis, in order not to 
reduce costs versus standard PN in adult patients, ω-3 
FA-containing PN would need to have a daily cost equal 
to €343.85 in France, €843.04 in Germany, €712.52 in 
Italy, €226.91 in Spain €925.91/£832.47 in the UK, and 
US$1826.62 in the US. Deterministic sensitivity analy-
ses, which rank the influence of key parameters on cost 
savings per patient, showed that across all six countries 
and both PN treatment regimens the mean difference of 
HLOS was the most influential factor, followed by the 
daily costs for critically ill patients (Additional file 1: Fig-
ure S4).
Discussion
ω-3 FA-containing PN has been associated with signifi-
cantly improved patient outcomes across a wide range 
of studies [5–7, 9–11, 43–45] and our recently published 
analyses on hospitalized patients concluded that ω-3 FA-
containing PN significantly improves clinical outcomes 
[8] while simultaneously leading to total cost savings in 
five European countries (France, Germany, Italy, Spain 
and the UK) and in the US when compared with stand-
ard PN [39]. The presented updated model indicates that 
the situation in ICU patients mirrors that of the overall 
hospital population: ω-3 FA-containing PN compared 
to standard PN is associated with significantly improved 
clinical outcomes and with concurrent cost reductions. 
This suggests that, from a hospital’s point of view, ω-3 
FA-containing PN is likely a dominant alternative to 
standard PN for ICU patients. The higher acquisition 
cost for ω-3 FA-containing PN in comparison to stand-
ard PN is offset by lower overall expenses due to shorter 
HLOS, ICU LOS and lower infection rates; demonstrat-
ing that overall costs rather than nutrition cost should 
be considered in treatment decisions. The impact of ω-3 
FA-containing PN on costs might be even greater when 
taking into consideration that at least 1 in 4 critically ill 
patients suffer from ICU-acquired weakness, a condition 
caused by hypercatabolism that results in severe loss of 
muscle mass, which is associated with poorer clinical 
outcomes such as higher hospital mortality, longer dura-
tion of mechanical ventilation and impaired long-term 
Fig. 4 HLOS in a all ICU patients and b critically ill ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: random sequence 
generation (selection bias); B: allocation concealment (selection bias); C: blinding of participants and personnel (performance bias); D: blinding 
outcome data (attrition bias); E: incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, confidence interval; 
FA, fatty acid; HLOS, hospital length of stay; ICU, intensive care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
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physical function [25–30]. Consequently, ICU patients 
often require subsequent rehabilitation, are unable to 
return to work or require nursing home care [46, 47].
Similar to the meta-analysis of all hospitalized patients 
[8], ω-3 FA-containing PN was associated with a better 
efficacy than standard PN in ICU patients. Compared 
to the overall population of hospitalized patients, ICU 
patients had a longer HLOS and a higher incidence of 
infection, which was to be expected in a more ill patient 
population. The reductions with ω-3 FA-containing 
PN regarding infection, sepsis and 30-day mortal-
ity were slightly less pronounced in ICU patients than 
Fig. 5 ICU LOS in a all ICU patients and b critically ill ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: random 
sequence generation (selection bias); B: allocation concealment (selection bias); C: blinding of participants and personnel (performance bias); D: 
blinding outcome data (attrition bias); E: incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, confidence 
interval; FA, fatty acid; ICU, intensive care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
Fig. 6 Length of mechanical ventilation in ICU patients. Risk of bias legend: +: high risk; −; low risk; blank: risk unclear. A: random sequence 
generation (selection bias); B: allocation concealment (selection bias); C: blinding of participants and personnel (performance bias); D: blinding 
outcome data (attrition bias); E: incomplete outcome data (attrition bias); F: selective reporting (reporting bias); G: other bias. CI, confidence interval; 
FA, fatty acid; ICU, intensive care unit; ω-3, omega-3; M–H, Mantel–Haenszel study weighting; PN, parenteral nutrition
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in the general hospitalized patient population. How-
ever, there was an even greater reduction in HLOS 
among ICU patients with ω-3 FA-containing PN than 
previously reported for all hospitalized patients (ICU 
patients: − 3.05 days [95% CI − 5.03; − 1.07]; hospitalized 
patients: − 2.14  days [95%  CI − 2.93; − 1.36]). Similarly, 
the subgroup of critically ill ICU patients experienced a 
greater treatment benefit with ω-3 FA-containing PN in 
terms of reduced ICU LOS compared with the general 
population of ICU patients or hospitalized patients (criti-
cally ill ICU patients: − 2.14 days [95% CI − 3.89; − 0.40]; 
all ICU patients: − 1.89 days [95% CI − 3.33; − 0.45]; hos-
pitalized patients: − 1.95  days [95%  CI − 3.49; − 0.42]). 
This suggests that ω-3 FA-containing PN may be par-
ticularly suited to benefit ICU patients who are critically 
ill (as defined by the authors of published data or with a 
mean ICU LOS > 48 h).
Despite the higher acquisition cost of ω-3 FA-contain-
ing PN, supplementation of ω-3 FA was associated with 
total cost savings in ICU patients. This cost reduction 
was even more significant in the ICU setting than in the 
general hospital setting for all five European countries 
analyzed [39]. The greater impact of ω-3 FA-containing 
PN on costs was likely due to the fact that daily costs for 
ICU patients are generally higher than for other hospital-
ized patients [20]. In European countries, such as Ger-
many, Italy, Spain and the UK, ICU costs vary to some 
extent, with the UK having the most expensive ICU care 
[48]. Daily ICU costs in the US, however, are significantly 
higher [49], suggesting that reduction in ICU LOS will 
particularly benefit countries with high daily costs per 
ICU patient. Due to the increased severity of illnesses in 
hospitalized patients and an aging population, ICU costs 
Table 1 Efficacy estimates: HLOS and  infection with  ω-3 
FA-containing PN and standard PN
FA, fatty acid; HLOS, hospital length of stay; ω-3, omega-3; PN, parenteral 
nutrition
Mean efficacy HLOS (days) Incidence 
of infections 
(%)
France ω-3 FA-containing PN 28.5 30
Standard PN 31.5 47
Germany ω-3 FA-containing PN 29.4 12
Standard PN 32.5 19
Italy ω-3 FA-containing PN 34.2 29
Standard PN 37.3 45
Spain ω-3 FA-containing PN 43.3 29
Standard PN 46.3 46
UK ω-3FA-containing PN 16.9 12
Standard PN 19.9 20
US ω-3 FA-containing PN 17.32 22
Standard PN 20.37 35
Table 2 Modeled costs for PN, infections and HLOS with ω-3 FA-containing PN and standard PN
Bold values indicate the expected difference in total hospital costs per PN patient
EUR, euro; GBP, pound sterling; FA, fatty acid; HLOS, hospital length of stay; ω-3, omega-3; PN, parenteral nutrition; SD, standard deviation; USD, US dollar
a GBP and USD converted to EUR using the average exchange rates of January 2020: GBP-EUR: 1.1759; USD-EUR: 0.9005
Mean costs ± SD (€) PN Infection HLOS Total
France ω-3 FA-containing PN 293 ± 152 344 ± 530 31,869 ± 20,825 32,507 ± 20,866
Standard PN 335 ± 171 543 ± 580 35,282 ± 20,825 36,159 ± 20,860
∆ − 42 ± 35 − 199 ± 782 − 3413 ± 0 − 3652 ± 783
Germany ω-3 FA-containing PN 880 ± 581 230 ± 639 45,783 ± 29,324 46,893 ± 29,375
Standard PN 804 ± 553 373 ± 781 50,528 ± 29,324 51,706 ± 29,347
∆ 76 ± 63 − 143 ± 1010 − 4745 ± 0 − 4813 ± 1011
Italy ω-3 FA-containing PN 918 ± 557 531 ± 838 37,928 ± 31,886 39,377 ± 31,934
Standard PN 579 ± 362 833 ± 923 41,308 ± 31,886 42,719 ± 31,915
∆ 339 ± 202 − 302 ± 1242 − 3380 ± 0 − 3342 ± 1254
Spain ω-3 FA-containing PN 345 ± 243 612 ± 949 41,543 ± 22,990 42,500 ± 23,056
Standard PN 222 ± 157 963 ± 1039 44,471 ± 22,990 45,656 ± 23,036
∆ 123 ± 88 − 351 ± 1402 − 2928 ± 0 − 3156 ± 1404
UKa ω-3 FA-containing PN 476 ± 220 101 ± 271 30,359 ± 35,183 30,936 ± 35,232
Standard PN 467 ± 216 166 ± 330 35,850 ± 35,183 36,481 ± 35,201
∆ 9 ± 75 − 65 ± 428 − 5491 ± 0 − 5546 ± 436
USa ω-3 FA-containing PN 180 ± 111 1437 ± 2731 50,352 ± 45,650 51,970 ± 45,773
Standard PN 51 ± 31 2288 ± 3150 59,217 ± 45,650 61,556 ± 45,751
∆ 128 ± 82 − 850 ± 5055 − 8865 ± 0 − 9586 ± 4157
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have increased over the past decades and are expected 
to rise even further in the future [50, 51]. In this con-
text, reducing overall costs may become an increasingly 
important outcome in the future.
The present meta-analysis is only partially comparable 
with the one previously conducted by Manzanares et al. 
[12], as it differs in the type of nutrition considered (we 
focus on total parenteral nutrition) and uses a different 
definition of critically ill (i.e., at least 5% mortality in 
the control group); it is nevertheless reassuring that the 
results of the two approaches compare well, with almost 
identical estimates of the effect on infection rate.
As both the meta-analysis and pharmacoeconomic 
analysis relied on the availability of published data 
regarding treatment effect and overall costs, one limita-
tion of this study was dated references. Additionally, the 
population of ICU patients reported is rather heteroge-
neous and dependent on the medical condition, which 
results in great variation regarding hospital and ICU 
LOS. However, sensitivity analyses have shown that the 
overall direction of the results, i.e., better clinical out-
comes at lower health care cost, is robust to reasonable 
variations of the context.
The accumulation of evidence regarding the improve-
ment of clinical outcomes with ω-3 FA-containing PN in 
comparison to standard PN [5–7, 9–11, 43–45] may con-
tribute to evidence-based treatment decisions and future 
clinical practice guidelines. The simultaneous cost sav-
ings with PN containing ω-3 FA, as shown here for ICU 
patients and previously for hospitalized patients in gen-
eral [39], may require consideration with respect to the 
best standard of care in PN.
Conclusions
This meta-analysis is the largest to date investigating the 
effects of different intravenous PN regimens on clinically 
important outcomes in the ICU. Here, we show that ω-3 
FA-containing PN is associated with a positive impact on 
clinical outcomes for ICU patients, such as reductions in 
infection rates and the duration of hospital and ICU stay. 
A pharmacoeconomic simulation revealed that ω-3 FA-
containing PN is likely a dominant alternative to standard 
PN from a hospital’s point of view for all of the five Euro-
pean countries analyzed (France, Germany, Italy, Spain 
and the UK) as well as for the US. Despite higher acquisi-
tion costs for ω-3 FA-containing PN, its superior efficacy 
makes it a cost-saving alternative. Here, we confirm the 
positive impact of ω-3 FA-containing PN demonstrated 
for hospitalized patients [8] in both the general popula-
tion of ICU patients and in the subgroup of critically ill 
ICU patients.
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